Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Yiu, ZZN; Ashcroft, DM; Evans, I; McElhone, K; Lunt, M; Smith, CH; Walton, S; Murphy, R; Reynolds, NJ; Ormerod, AD; +3 more... Griffiths, CEM; Warren, RB; BADBIR Study Group; (2019) Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). BRITISH JOURNAL OF DERMATOLOGY, 180 (2). pp. 329-337. ISSN 0007-0963 DOI: https://doi.org/10.1111/bjd.17036

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1111/bjd.17036

Abstract

Share

Download

Filename: Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of .pdf

Licence: Creative Commons: Attribution 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar